GB9321855D0 - 1,4-piperazine derivatives - Google Patents

1,4-piperazine derivatives

Info

Publication number
GB9321855D0
GB9321855D0 GB939321855A GB9321855A GB9321855D0 GB 9321855 D0 GB9321855 D0 GB 9321855D0 GB 939321855 A GB939321855 A GB 939321855A GB 9321855 A GB9321855 A GB 9321855A GB 9321855 D0 GB9321855 D0 GB 9321855D0
Authority
GB
United Kingdom
Prior art keywords
piperazine derivatives
piperazine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB939321855A
Other versions
GB2271774A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of GB9321855D0 publication Critical patent/GB9321855D0/en
Publication of GB2271774A publication Critical patent/GB2271774A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9321855A 1992-10-26 1993-10-22 Piperazine derivatives Withdrawn GB2271774A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929222486A GB9222486D0 (en) 1992-10-26 1992-10-26 Therapeutic agents

Publications (2)

Publication Number Publication Date
GB9321855D0 true GB9321855D0 (en) 1993-12-15
GB2271774A GB2271774A (en) 1994-04-27

Family

ID=10724077

Family Applications (2)

Application Number Title Priority Date Filing Date
GB929222486A Pending GB9222486D0 (en) 1992-10-26 1992-10-26 Therapeutic agents
GB9321855A Withdrawn GB2271774A (en) 1992-10-26 1993-10-22 Piperazine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB929222486A Pending GB9222486D0 (en) 1992-10-26 1992-10-26 Therapeutic agents

Country Status (1)

Country Link
GB (2) GB9222486D0 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2719474B1 (en) 1994-05-05 1996-05-31 Oreal Use of a substance P antagonist in a cosmetic composition and composition obtained.
FR2719476B1 (en) * 1994-05-05 1997-05-23 Oreal Use of a substance P antagonist in a cosmetic composition and composition obtained.
FR2728265A1 (en) * 1994-12-19 1996-06-21 Oreal USE OF A SUBSTANCE P ANTAGONIST IN A PHARMACEUTICAL COMPOSITION
FR2728165A1 (en) † 1994-12-19 1996-06-21 Oreal USE OF AN ANTAGONIST OF SUBSTANCE P FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN
WO1996028441A1 (en) * 1995-03-15 1996-09-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists
FR2732598B1 (en) 1995-04-10 1997-05-09 Oreal USE OF ALKALINE EARTH METAL SALT FOR THE TREATMENT OF PRURITUS AND EYE OR PALPEBRAL DYSESTHESIA
EP0737471A3 (en) * 1995-04-10 2000-12-06 L'oreal Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom
ATE277021T1 (en) * 1995-04-13 2004-10-15 Aventis Pharma Inc NEW SUBSTITUTED PIPERAZINE DERIVATIVES WITH TACHYKINE RECEPTOR ANTAGONISTIC EFFECT
GB9510600D0 (en) * 1995-05-25 1995-07-19 Fujisawa Pharmaceutical Co Piperazine derivatives
FR2737408B1 (en) * 1995-07-31 1997-09-05 Oreal USE OF A BRADYKININE ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED
FR2738741B1 (en) * 1995-09-19 1997-12-05 Oreal COMPOSITION FOR DYEING KERATINIC FIBERS, CONTAINING AN ANTAGONIST OF SUBSTANCE P
FR2740341B1 (en) * 1995-10-26 1997-12-19 Oreal USE OF LANTHANIDE SALT, TIN, ZINC, MANGANESE, YTTRIUM, COBALT, BARIUM, STRONTIUM IN A SKIN COMPOSITION
FR2740335B1 (en) * 1995-10-26 1997-12-19 Oreal USE OF LANTHANIDE, LITHIUM, TIN, ZINC, MANGANESE OR YTTRIUM SALT AS A SUBSTANCE P ANTAGONIST
HUP9901037A3 (en) * 1995-12-18 2001-11-28 Fujisawa Pharmaceutical Co Piperazine derivatives,preparation and use thereof, pharmaceutical compositions containing these compounds
KR100885986B1 (en) 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
US6787543B2 (en) 2000-06-29 2004-09-07 Fujisawa Pharmaceutical Co., Ltd. Benzhydryl derivatives
NZ523456A (en) 2000-07-11 2004-11-26 Albany Molecular Res Inc Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US6906074B2 (en) * 2002-02-22 2005-06-14 Nippon Zoki Pharmaceutical Co., Ltd. 2-phenylpiperazine derivatives
KR101389246B1 (en) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (en) 2005-05-17 2012-04-15 Merck Sharp & Dohme CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
JP5258561B2 (en) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド Aryl and heteroaryl substituted tetrahydrobenzazepines and their use to block reuptake of norepinephrine, dopamine and serotonin
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (en) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US20100105688A1 (en) 2007-01-24 2010-04-29 Glaxo Group Limited Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
JP5501227B2 (en) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 4-Carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (en) 2008-06-04 2010-07-28 Bristol Myers Squibb Co CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2010247849B2 (en) 2009-05-12 2015-11-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
ES2528404T3 (en) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Crystal forms of (S) -7 - ([1,2,4] triazol [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4- tetrahydroisoquinoline and its uses
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
PE20121172A1 (en) 2009-10-14 2012-09-05 Merck Sharp & Dohme PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2745848C2 (en) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. RNA INTERFERENCE-MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION WITH THE USE OF A SMALL INTERFERING NUCLEIC ACID (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
RS56680B1 (en) 2012-11-28 2018-03-30 Merck Sharp & Dohme Compositions and methods for treating cancer
ES2707305T3 (en) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopyridines substituted as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Also Published As

Publication number Publication date
GB2271774A (en) 1994-04-27
GB9222486D0 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
GB9321855D0 (en) 1,4-piperazine derivatives
AP9300478A0 (en) 1,5 benzodiazepine derivatives
ZA934603B (en) thiazolylvinylphenyl derivatives.
HK1011350A1 (en) Arylamide derivatives
GB9305306D0 (en) Pyrrolo-pyridazione derivatives
HU9301955D0 (en) Benzophenone-hydrazone derivatives
HU9403110D0 (en) 1[2h-1-benzopyran-2-on-8-yl]-piperazine derivatives
HU9302314D0 (en) 1,4-benzodioxane derivatives
HU9300744D0 (en) 2-oxo-quinoline derivatives
HU9301112D0 (en) Propenoyl-imidazole derivatives
HU9301616D0 (en) New thio-semicarbazone derivatives
HU9400745D0 (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
GB2271564B (en) Thioalkylthio carbacephalosporin derivatives
GB2270913B (en) Chlordifluoromethoxyphenyl derivatives
HU908313D0 (en) New 15-nitro-2betha, 3betha-dihydro- and 15-nitro-2betha, 3 betha,6,7-tetrahydro-tabersonine derivatives
GB9322017D0 (en) 1,4-piperazine derivatives
EP0565961A3 (en) Ethyl-triazolyl derivatives
HU9202296D0 (en) 3,4-dehydro-piperidine derivatives
ZA936048B (en) Novel 3-oxadiazolyl-1,6-napthyridine derivatives
HU9302058D0 (en) Thia-diazinone derivatives
GB9223244D0 (en) Phenylpyrazine derivatives
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives
HU9301696D0 (en) Pyrimidofuroxane derivatives
HU9202008D0 (en) New 4-methyl-2-imidazolinone derivatives

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)